Eli Lilly & Co. vs. Sagimet Biosciences Inc. Series A Common Stock
LLY
Eli Lilly & Co.
$1180.16 -2.39%
VS SGMTSagimet Biosciences Inc. Series A Common Stock
$10.55 +13.69%
Eli Lilly & Co. and Sagimet Biosciences Inc. Series A Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| LLY | SGMT | |
|---|---|---|
| Market Cap | $1.09 trillion | $655.77 million |
| Revenue (TTM) | $79.67 billion | — |
| Net Income (TTM) | $26.71 billion | — |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | SGMT | |
|---|---|---|
| P/E Ratio | 39.62 | — |
| Price / Book | 32.11 | — |
| Price / Sales | 13.65 | — |
LLY and SGMT split the valuation factors evenly.
Profitability
| LLY | SGMT | |
|---|---|---|
| Net Margin | 33.53% | — |
| Return on Equity | 78.84% | — |
LLY and SGMT split the profitability factors evenly.
Dividend
| LLY | SGMT | |
|---|---|---|
| Dividend Yield | 0.59% | — |
| Payout Ratio | 23.23 | — |
LLY and SGMT split the dividend factors evenly.
Risk & Sentiment
| LLY | SGMT | |
|---|---|---|
| Short Interest | 1.29% | 0.89% |
SGMT leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, SGMT overview, SGMT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.